2018
DOI: 10.3892/mmr.2018.9070
|View full text |Cite
|
Sign up to set email alerts
|

Candesartan targeting of angiotensin II type 1 receptor demonstrates benefits for hypertension in pregnancy via the NF‑κB signaling pathway

Abstract: Hypertensive disorders may be a complication of pregnancy and are characterized by the high blood pressure. Evidence suggests that alterations in the renin-angiotensin-aldosterone system and the sympathetic nervous system are associated with gestational hypertension. Angiotensin II type 1 receptor (Ang-IITR) is a potential target in the progression of gestational hypertension. Candesartan is selective Ang-IITR antagonist that may act against vasoconstriction and reduces peripheral vascular resistance. The aim … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
12
1

Year Published

2019
2019
2022
2022

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(13 citation statements)
references
References 52 publications
0
12
1
Order By: Relevance
“…26 More emerging evidence revealed that candesartan could effectively inhibit glial activation, 27 reduce inflammatory response, 28 and block NF-κB activity. 24 However, in the present study, we showed that candesartan inhibited inflammatory response and induced the shift of microglia from pro-inflammatory M1 to anti-inflammatory M2 phenotype, which may be associated with TLR4-mediated NF-κB pathway.…”
Section: Discussioncontrasting
confidence: 59%
“…26 More emerging evidence revealed that candesartan could effectively inhibit glial activation, 27 reduce inflammatory response, 28 and block NF-κB activity. 24 However, in the present study, we showed that candesartan inhibited inflammatory response and induced the shift of microglia from pro-inflammatory M1 to anti-inflammatory M2 phenotype, which may be associated with TLR4-mediated NF-κB pathway.…”
Section: Discussioncontrasting
confidence: 59%
“…In the human model of forearm blood flow, ET‐1 functions as a vasoconstriction regulator and the application of antagonists of ETAR and ETBR has demonstrated that ETAR lowers blood flow to ET‐1, where ETBR is a vasodilator 35 . Zhao et al reported that the NF‐κB pathway may contribute to candesartan‐induced initiation and progression of PIH 36 . Furthermore, betaine treatment has been shown to attenuate pulmonary arterial hypertension through the inhibition of inflammatory response by inactivating the NF‐κB pathway 37 .…”
Section: Discussionmentioning
confidence: 98%
“…Recently, it has been shown to ameliorate brain inflammation associated with Alzheimer's disease [16] and to induce neuroprotective effects in patients suffering from Parkinson's disease [17]. Moreover, it has been shown to reduce inflammation and mucin production in patients with allergic asthma [18] and to induce benefits in a gestational hypertension mouse model [19].…”
Section: Introductionmentioning
confidence: 99%